MARKET

VERA

VERA

Vera Therapeutics, Inc.
NASDAQ
36.57
-0.04
-0.11%
Opening 12:36 05/12 EDT
OPEN
36.34
PREV CLOSE
36.61
HIGH
37.23
LOW
35.95
VOLUME
246.82K
TURNOVER
--
52 WEEK HIGH
56.05
52 WEEK LOW
18.76
MARKET CAP
2.63B
P/E (TTM)
-6.6026
1D
5D
1M
3M
1Y
5Y
1D
Analyst Reiterates Buy on Vera as Atacicept Progress and Strong Cash Position Support Unchanged $110 Price Target
TipRanks · 6h ago
Vera Therapeutics (VERA) Receives a Buy from Guggenheim
TipRanks · 1d ago
Weekly Report: what happened at VERA last week (0504-0508)?
Weekly Report · 1d ago
Vera Therapeutics grants inducement equity awards to 10 new hires, sets options at $35.51
PUBT · 3d ago
VERA THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 3d ago
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 4d ago
Wedbush Sticks to Its Hold Rating for Vera Therapeutics (VERA)
TipRanks · 4d ago
Vera Therapeutics: Buy Rating Reiterated on Strong Atacicept Outlook and Launch Readiness; $73 Price Target Maintained
TipRanks · 4d ago
More
About VERA
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.

Webull offers Vera Therapeutics, Inc stock information, including NASDAQ: VERA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VERA stock methods without spending real money on the virtual paper trading platform.